Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants
Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Summary
The purpose of this study is to evaluate the safety and tolerability of single ascending doses of MORF-440 administered to healthy participants single-ascending dose (SAD) and maximum ascending dose (MAD) substudy.
Official title: A Phase 1, First-in-human Study of MORF-440 in Healthy Participants, Including Single and Multiple Ascending Dose Cohorts
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2025-02-19
Completion Date
2026-03
Last Updated
2026-01-20
Healthy Volunteers
Yes
Conditions
Interventions
LY4292009
Administered orally
Placebo
Administered orally.
Locations (1)
Altasciences Company Inc.
Mount Royal, Canada